Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · IEX Real-Time Price · USD
0.890
-0.034 (-3.67%)
At close: Jul 2, 2024, 4:00 PM
0.880
-0.010 (-1.09%)
After-hours: Jul 2, 2024, 7:38 PM EDT

Xilio Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year
Current20232022202120202019
Market Capitalization
331574440--
Market Cap Growth
-65.84%-79.50%-83.19%---
Enterprise Value
5-19-282600-30
PE Ratio
--0.20-0.84-5.80--
PB Ratio
1.280.410.702.37--
P/FCF Ratio
-0.55-0.22-0.95-5.37--
P/OCF Ratio
-0.55-0.22-0.98-5.44--
EV/EBITDA Ratio
-0.030.250.33-3.51-0.011.78
EV/EBIT Ratio
-0.030.240.32-3.44-0.011.76
EV/FCF Ratio
-0.040.270.36-3.18-0.011.64
Debt / Equity Ratio
0.350.340.190.11-0.25-0.63
Debt / EBITDA Ratio
-0.13-0.17-0.23-0.28-0.39-1.09
Debt / FCF Ratio
-0.17-0.18-0.26-0.25-0.55-1.00
Quick Ratio
2.112.905.7715.620.949.42
Current Ratio
2.193.025.9015.850.939.81
Return on Equity (ROE)
-155.60%-126.60%-65.10%-148.40%97.90%-
Return on Assets (ROA)
-90.50%-89.20%-52.60%-59.60%-111.50%-
Return on Capital (ROIC)
-210.59%-160.41%-70.99%-36.44%87.91%174.69%
Earnings Yield
-216.00%-504.38%-119.38%-17.25%--
FCF Yield
-164.95%-456.20%-105.00%-18.62%--
Buyback Yield / Dilution
-1.75%-0.38%-388.59%-970.34%86.53%-
Total Shareholder Return
-1.75%-0.38%-388.59%-970.34%86.53%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).